
|Videos|March 18, 2016
Dr. Judy Boughey on Neoadjuvant Endocrine Therapy in Breast Cancer
Author(s)Judy Boughey, MD
Boughey says an ongoing national clinical trial is looking at patients with ER+ breast cancer and treating them with neoadjuvant endocrine therapy.
Advertisement
Judy Boughey, MD, associate professor of surgery, director, Breast Surgical Oncology Training Program, Mayo Clinic, discusses the coming usefulness of neoadjuvant endocrine therapy in breast cancer. Boughey says an ongoing national clinical trial is looking at patients with ER+ breast cancer and treating them with neoadjuvant endocrine therapy. Researchers are taking biopsies several weeks into the study as well to monitor the proliferation rate of a patient's tumor.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
4
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
5








































